Barclays raised the firm’s price target on Alignment Healthcare (ALHC) to $9 from $8 and keeps an Underweight rating on the shares following the Q4 EBITDA beat.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare: Strong Financial Performance and Promising Outlook Justify Buy Rating
- Alignment Healthcare Reports Strong Growth and Positive Outlook
- Alignment Healthcare reports Q4 EPS (16c), consensus (8c)
- Alignment Healthcare sees Q1 adjusted EBITDA $2M-$10M
- Alignment Healthcare sees FY25 adjusted EBITDA $35M-$60M